Direct compression of ARC-0600 Pharma Grade API into immediate-release tablet cores is implemented only after powder rheology has been confirmed on a Schulze RST-XS ring shear tester with a flow function coefficient not lower than 4.0 at 3 kPa normal stress. Incoming API particle size distribution is determined by laser diffraction according to USP <429> and ISO 13320:2020; direct compression is sensitive to fines below 10 µm, so D10 should remain above 15 µm, while D90 is typically held below 150 µm to reduce punch filming and sticking. If the relative humidity in the processing suite exceeds 60% RH, the API is pre-dried in a fluid-bed dryer at 40 °C ± 2 °C for not less than 4 h with inlet air dew point no higher than −10 °C. A representative batch is composed of 12.0 wt% ARC-0600, 84.5 wt% microcrystalline cellulose PH-102, 2.0 wt% crospovidone, 1.0 wt% colloidal silicon dioxide, and 0.5 wt% magnesium stearate. Blending is performed in a 600 L bin blender at 15 rpm for 20 min, with magnesium stearate added only in the final 3 min to limit shear-induced hydrophobicity. Compression is carried out on a 16-station rotary tablet press fitted with B-tooling; precompression force is set at 3–5 kN, main compression force at 8–18 kN, and turret speed at 25–40 rpm. Ejection force is monitored continuously and maintained below 800 N to avoid picking and chipping. Blend uniformity is evaluated per USP <905> with Stage 1 acceptance value L1 ≤15.0; tablet hardness is measured per USP <1217>; disintegration per USP <701> in 900 mL purified water at 37 °C ± 2 °C; and dissolution per USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.01 N HCl. The terminal immediate-release tablet has a target mass of 250 mg, hardness 4–8 kp, friability below 0.8% after 100 rotations per USP <1216>, and not less than 80% release in 30 min for a typical immediate-release acceptance criterion. This direct compression route is incompatible with API lots having bulk density below 0.35 g/cm³ and with formulations requiring more than 2.0 wt% sodium starch glycolate, which may promote over-drying and capping under extended precompression dwell times.

How Does Roller Compaction Affect ARC-0600 Recompression Potential?

Only after direct compression has been ruled out by flow function coefficient below 4.0 or by segregation tendency exceeding 5.0% RSD in full-scale hopper discharge is dry granulation by roller compaction selected for ARC-0600. A representative dry granulation formulation is 20.0 wt% ARC-0600, 73.0 wt% mannitol SD200, 5.0 wt% pregelatinized starch, and 2.0 wt% croscarmellose sodium, with an external phase of 1.0 wt% magnesium stearate added after milling. The preblend is compacted on an Alexanderwerk WP 120 roller compactor at roll force 5–15 kN/cm, roll gap 1.5–2.5 mm, roll speed 3–8 rpm, and roll surface temperature below 40 °C to avoid stickiness. Ribbon solid fraction is controlled between 0.55 and 0.70 as calculated from envelope density by helium pycnometry; ribbon porosity below 0.35 may indicate overcompaction and loss of recompression potential, while porosity above 0.45 produces weak granules that generate excessive fines. The ribbons are milled through a Comil U5 fitted with a 1.0 mm round-hole screen at impeller speed 2000–3500 rpm, yielding granule D50 between 250 µm and 500 µm by USP <786>. Granule loss on drying is controlled by USP <731> at ≤2.0%, and the final blend is tested for content uniformity by USP <905> with relative standard deviation not more than 5.0%. In-process monitoring is executed under 21 CFR 211.110. The resulting granules are filled into hard capsules or compressed into tablet cores with tensile strength not less than 1.2 MPa; ejection force in tableting should remain below 900 N. Roller compaction is incompatible with API lots having D90 above 300 µm without pre-milling, because coarse API domains persist as surface-enriched agglomerates after milling and compromise blend uniformity.

When ARC-0600 exhibits unacceptable flow that cannot be corrected by dry granulation and is chemically stable under aqueous conditions, high-shear wet granulation delivers densified granules with improved die filling and reduced dust generation. A representative aqueous granulation formula is 25.0 wt% ARC-0600, 60.0 wt% lactose monohydrate 200M, 10.0 wt% microcrystalline cellulose PH-101, 3.0 wt% crospovidone, and 2.0 wt% povidone K30 as binder. Dry blending is performed in a 25 L high-shear granulator at impeller speed 150–300 rpm and chopper speed 1500 rpm for 3 min; purified water or a 5 wt% povidone K30 solution is sprayed at 80–150 g/min until the impeller torque rises 30–50% above the dry-mix baseline. Endpoint control is based on torque rise and wet mass visual consistency rather than a fixed water volume, because the water-binding capacity of ARC-0600 varies with particle morphology. The wet mass is dried in a GPGC-5 fluid-bed dryer with inlet air temperature 50–65 °C and product temperature not exceeding 40 °C, until loss on drying by USP <731> is 1.5–2.5%. Dried granules are milled through a 1.0 mm oscillating screen and blended with 1.0 wt% magnesium stearate for 3 min at 15 rpm. Granule particle size distribution is monitored by USP <786>; friability of the dried granules is measured by rotating 10 g of granule with 200 glass beads for 15 min at 25 rpm, and acceptable granule friability is below 15%. The terminal tablet cores are compressed to 450 mg target mass with hardness 8–12 kp, disintegration not more than 15 min by USP <701>, and immediate-release dissolution by USP <711> Apparatus 2 in 900 mL of 0.01 N HCl at 50 rpm. In-process controls are executed under 21 CFR 211.110 and production records are maintained under 21 CFR 211.186; if organic binder solvents are substituted, residual solvent levels must comply with ICH Q3C Class 2 or Class 3 limits. Aqueous granulation is not appropriate if forced degradation under ICH Q1A(R2) demonstrates more than 0.5% total degradation at 40 °C / 75% RH for 4 weeks.

Capsule Plug Formation and Low-Dose Content Uniformity

Low-dose hard capsule filling with ARC-0600 requires a staged pre-blend to prevent segregation of the API and to achieve a compressible plug that maintains dose uniformity. A premix is prepared by blending 1 part micronized ARC-0600 with 9 parts lactose monohydrate 200M for 10 min in a 300 L bin blender at 20 rpm; this premix is then diluted with microcrystalline cellulose PH-102 to a final API concentration of 2.0 wt%, plus 2.0 wt% crospovidone, 0.5 wt% colloidal silicon dioxide, and 0.5 wt% magnesium stearate. The final blend is mixed for an additional 15 min at 15 rpm, because higher shear or longer mixing can over-lubricate the plug and reduce capsule disintegration. Encapsulation is performed on a Bosch GKF 720 dosator-type machine at 60,000 capsules/h; tamping pin stations are set to produce plug heights between 10 mm and 13 mm for size 3 hard gelatin or HPMC shells. Fill weight is monitored by in-process checkweighing every 10 min, and the average fill weight is maintained within ±3.0% of target. The shell moisture content is kept below 13% for gelatin and below 5% for HPMC to avoid brittle shell failure. Content uniformity is assessed by USP <905> with Stage 1 L1 ≤15.0; dissolution uses USP <711> Apparatus 1 at 100 rpm in 900 mL of 0.01 N HCl. In-process controls comply with 21 CFR 211.110. The resulting capsule has a total fill weight of 250 mg and a shell size of 3; dose strength is defined by the approved application and may require a lower API concentration if the blend shows electrostatic adhesion to machine surfaces. Capsule filling is not recommended when API D90 exceeds 200 µm, because coarse particles create plug porosity gradients and increase fill weight variability beyond the ±3.0% control limit.

Injectable Solution Terminal Sterilization and Glass Container Compatibility

For parenteral use, ARC-0600 is dissolved in Water for Injection that meets the USP monograph requirements, with pH adjusted to the approved range using 0.1 N HCl or 0.1 N NaOH; if the marketing authorization does not establish a range, pH is developed within 4.0–7.0 based on forced degradation data. A representative bulk solution at 25.0 mg/mL ARC-0600 contains 9.0 g/L sodium chloride for isotonicity and 10 mM citrate or acetate buffer if pH drift is observed; published data for ARC-0600 buffer compatibility is limited, so forced degradation under ICH Q1A(R2) should identify pH-sensitive degradation products before the batch formula is locked. The bulk solution is prefiltered through a 0.45 µm PVDF membrane and then sterile-filtered through two 0.22 µm sterilizing-grade membranes in series. If the API is thermally stable, terminal sterilization is executed at 121 °C for 15 min with a validated F0 not less than 8 min; otherwise aseptic filling is conducted in an ISO 5 environment under ISO 14644-1 classification. Finished product testing includes sterility by USP <71>, bacterial endotoxins by USP <85> with a limit derived from the maximum bolus dose, sub-visible particulate matter by USP <788> with limits of ≥10 µm ≤6000 per vial and ≥25 µm ≤600 per vial for containers of ≤100 mL, visible particulates by USP <790>, pH by USP <791>, and osmolality by USP <785> at 270–328 mOsm/kg for an isotonic presentation. The solution is filled into 10 mL Type I borosilicate glass vials under nitrogen headspace and sealed with bromobutyl rubber stoppers; glass delamination is assessed by USP <1660>. Injection formulation is incompatible with phosphate buffers if solubility studies show ARC-0600 forms insoluble phosphate salts; compatibility with chloride-containing stoppers is confirmed by extractables and leachables testing under USP <1663> and USP <1664>.

Lyophilization is selected when terminal sterilization of ARC-0600 solution presents unacceptable degradation risk or when the drug product requires a dry powder presentation for reconstitution. The pre-lyophilization solution is formulated with 5.0 wt% ARC-0600, 3.0 wt% mannitol, 0.5 wt% trehalose dihydrate, and Water for Injection. The solution is sterile-filtered through a 0.22 µm membrane and filled at 10 mL per 20 mL Type I glass vial. The freeze-drying cycle begins with shelf cooling to -40 °C at 1 °C/min and holding for 2 h; annealing at -10 °C for 1–2 h may be used if mannitol crystallization is required, but the annealing temperature must remain below the collapse temperature measured by freeze-dry microscopy. Primary drying is conducted at shelf temperature -25 °C and chamber pressure 75–100 mTorr for 24–36 h, with product temperature monitored by resistance thermal detectors and kept below the collapse boundary. Secondary drying raises shelf temperature to 30 °C for 4–8 h, producing residual moisture by Karl Fischer USP <921> Method Ic not more than 1.0%. Aseptic operations are controlled under 21 CFR 211.113. The lyophilized cake is evaluated for appearance, reconstitution time, sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788>, visible particulates by USP <790>, and container closure integrity by USP <1207>. The terminal product is a lyophilized cake for reconstitution with 10 mL Sterile Water for Injection; reconstitution should yield a clear solution in ≤2 min without visible agglomerates. Collapse or meltback is rejected under visual inspection and indicates a failed lyophilization cycle; high residual moisture above 1.0% may reduce shelf-life stability and is controlled by extending secondary drying within the validated design space.